In the ever-evolving field of diabetes management, glucagon-like peptide-1 receptor agonists have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent novel https://andrewbwoy104745.ka-blogs.com/92317349/novel-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide